The Use of Statins Following a Left Atrial Catheter Ablation Procedure to Prevent Atrial Fibrillation

Completed · Phase 4 · Has a placebo group

Conditions studied: Atrial Fibrillation, Arrhythmia, Inflammation, Endothelial Dysfunction

In brief

To investigate whether statin therapy utilizing the drug Lipitor (atorvastatin) might be effective in preventing short-and long-term atrial fibrillation (AF) following a left atrial ablation procedure. We further hypothesize this reduction will result from diminished peri-procedural inflammation, which will be reflected in lower C-Reactive Protein (CRP) values in the blood.

Key facts

Study ID

NCT00579098

Run by

Mayo Clinic

People needed

125

Starts

2007-12-01

Expected to finish

2011-12-01

Last updated by the study team

2014-04-23

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients > or = to 18 years of age
• Clinically indicated left atrial ablation procedure for atrial fibrillation

You may not qualify if…

• Known malignancy
• Known inflammatory disease
• Surgery or trauma or myocardial infarction in the previous month
• Known contraindication to statin therapy
• Elevated liver enzymes above two times the upper limit of normal
• Patients already receiving therapy with any statin, niacin or fibrates at the time of their randomization

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.